Get started
EDITAS MEDICINE INC COM USD0.0001EDITAS MEDICINE INC COM USD0.0001EDITAS MEDICINE INC COM USD0.0001

EDITAS MEDICINE INC COM USD0.0001

No trades
See on Supercharts
Overview
Financials News Ideas Discussions Technicals Forecast Seasonals

0IFK chart


Full chart

0IFK upcoming earnings

Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—

Key stats


Market capitalization
‪198.94 M‬ USD
Dividend yield (indicated)
—
Price to earnings Ratio (TTM)
—
Basic EPS (TTM)
−2.562 USD
Net income (FY)
‪−153.22 M‬ USD
Revenue (FY)
‪78.12 M‬ USD
Shares float
‪81.77 M‬
Beta (1Y)
2.04

Employees


Employees (FY)
265
Change (1Y)
+39 +17.26%
Revenue / Employee (1Y)
‪294.80 K‬ USD
Net income / Employee (1Y)
‪−578.18 K‬ USD

About Editas Medicine, Inc.


Sector
Health Technology
Industry
Biotechnology
CEO
Gilmore O’Neill
Website
editasmedicine.com
Headquarters
Cambridge
Founded
2013
FIGI
BBG00JRQRZL1
Editas Medicine, Inc. engages in the development and commercialization of genome editing technology. Its technology includes clustered, regularly interspaced short palindromic repeats (CRISPR), and CRISPR associated protein 9 (Cas9). The company was founded by Feng Zhang, Jennifer A. Doudna, George McDonald Church, J. Keith Joung and David R. Liu in September 2013 and is headquartered in Cambridge, MA.

Financials


Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:—
‪0.00‬

0IFK news



Ideas



See all ideas 

Technicals

Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Analyst rating


An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Seasonals


Displays a symbol's price movements over previous years to identify recurring trends.

Frequently Asked Questions


The current price of 0IFK is 2.399 USD — it has decreased by −0.86% in the past 24 hours. Watch EDITAS MEDICINE INC COM USD0.0001 stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on LSE exchange EDITAS MEDICINE INC COM USD0.0001 stocks are traded under the ticker 0IFK.
0IFK stock has fallen by −19.49% compared to the previous week, the month change is a −36.53% fall, over the last year EDITAS MEDICINE INC COM USD0.0001 has showed a −76.66% decrease.
We've gathered analysts' opinions on EDITAS MEDICINE INC COM USD0.0001 future price: according to them, 0IFK price has a max estimate of 15.00 USD and a min estimate of 4.00 USD. Watch 0IFK chart and read a more detailed EDITAS MEDICINE INC COM USD0.0001 stock forecast: see what analysts think of EDITAS MEDICINE INC COM USD0.0001 and suggest that you do with its stocks.
0IFK reached its all-time high on Jan 8, 2021 with the price of 98.195 USD, and its all-time low was 2.600 USD and was reached on Nov 15, 2024. View more price dynamics on 0IFK chart.
See other stocks reaching their highest and lowest prices.
0IFK stock is 6.47% volatile and has beta coefficient of 2.04. Track EDITAS MEDICINE INC COM USD0.0001 stock price on the chart and check out the list of the most volatile stocks — is EDITAS MEDICINE INC COM USD0.0001 there?
Today EDITAS MEDICINE INC COM USD0.0001 has the market capitalization of ‪198.94 M‬, it has decreased by −13.00% over the last week.
Yes, you can track EDITAS MEDICINE INC COM USD0.0001 financials in yearly and quarterly reports right on TradingView.
EDITAS MEDICINE INC COM USD0.0001 is going to release the next earnings report on Feb 26, 2025. Keep track of upcoming events with our Earnings Calendar.
0IFK earnings for the last quarter are −0.75 USD per share, whereas the estimation was −0.75 USD resulting in a −0.40% surprise. The estimated earnings for the next quarter are −0.33 USD per share. See more details about EDITAS MEDICINE INC COM USD0.0001 earnings.
EDITAS MEDICINE INC COM USD0.0001 revenue for the last quarter amounts to ‪61.00 K‬ USD, despite the estimated figure of ‪3.93 M‬ USD. In the next quarter, revenue is expected to reach ‪30.73 M‬ USD.
0IFK net income for the last quarter is ‪−62.14 M‬ USD, while the quarter before that showed ‪−67.61 M‬ USD of net income which accounts for 8.08% change. Track more EDITAS MEDICINE INC COM USD0.0001 financial stats to get the full picture.
No, 0IFK doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Nov 21, 2024, the company has 265.00 employees. See our rating of the largest employees — is EDITAS MEDICINE INC COM USD0.0001 on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. EDITAS MEDICINE INC COM USD0.0001 EBITDA is ‪−222.63 M‬ USD, and current EBITDA margin is −208.80%. See more stats in EDITAS MEDICINE INC COM USD0.0001 financial statements.
Like other stocks, 0IFK shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade EDITAS MEDICINE INC COM USD0.0001 stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So EDITAS MEDICINE INC COM USD0.0001 technincal analysis shows the sell today, and its 1 week rating is strong sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating EDITAS MEDICINE INC COM USD0.0001 stock shows the sell signal. See more of EDITAS MEDICINE INC COM USD0.0001 technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.